• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

6-month androgen deprivation therapy fails to show non-inferior survival


A 6-month course of post-irradiation androgen deprivation therapy failed to demonstrate non-inferior survival compared to 3 years of adjuvant androgen deprivation in patients with locally advanced prostate cancer.

Prolonged androgen suppression resulted in a 5-year overall survival of 85.3% with prolonged androgen deprivation therapy versus 80.6% for the abbreviated course, investigators in a multicenter European trial reported at the 2007 American Society of Clinical Oncology annual meeting here. The difference translated to a mortality hazard ratio of 1.43 (96.4% CI: 1.04-1.98) for 6 months' hormonal treatment, which did not meet the trial's definition of non-inferiority.

More than a decade ago, Dr. Bolla and colleagues in the European Organization for Research and Treatment of Cancer (EORTC) established 3 years of adjuvant hormonal treatment as the standard of care for patients with locally advanced prostate cancer (N Engl J Med 1997; 337:295-300). Whether an abbreviated course of androgen deprivation would work just as well had not been determined.

EORTC investigators randomized 1,117 patients with locally advanced prostate cancer to 6 months or 36 months of post-irradiation androgen deprivation therapy. The primary objective was to demonstrate the non-inferiority of short-course adjuvant therapy compared to standard treatment. Non-inferiority was defined as a mortality hazard ratio of ≤1.35 for abbreviated androgen deprivation versus standard therapy.

All patients received a 70-Gy total dose of radiation in the form of external beam radiation therapy, followed by 6 months of combined androgen ablation. The patients were then randomized to no further hormonal treatment or to 30 months of additional androgen deprivation with a leuteinizing hormone-releasing hormone agonist.

Dr. Bolla reported that 147 patients did not receive randomized therapy, primarily because of toxicity (19.7%) and patient refusal (38.1%). That left 970 patients available for outcome analysis.

The trial was stopped early after a planned interim analysis suggested futility for the comparison and a clear advantage for prolonged androgen deprivation. After a median follow-up of 5.2 months, the short course of adjuvant androgen deprivation was associated with a mortality of 20.7% versus 15.0% among patients treated for 36 months. The resulting mortality hazard ratio of 1.43 failed to meet the pre-specified non-inferiority definition of ≤1.35.

When the trial was stopped, clinical progression-free survival was 81.8% with prolonged adjuvant therapy and 69% with abbreviated treatment (p<.0001). Biochemical progression-free survival was 78.27% among patients who received 3 years of adjuvant therapy versus 58.93% in those who received only 6 months of hormonal treatment (p<.0001). Assessment of global health status/quality of life demonstrated no difference between the treatment groups.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Leo Dreyfuss, MD, answers a question during a Zoom video interview
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.